APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pigmented Villonodular Synovitis Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pigmented Villonodular Synovitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025171 pages

Choose your research edition.

Industry ResearchPigmented Villonodular Synovitis Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Pigmented Villonodular Synovitis Drug Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal Pigmented Villonodular Synovitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pigmented Villonodular Synovitis Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pigmented Villonodular Synovitis Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Pigmented Villonodular Synovitis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pigmented Villonodular Synovitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pigmented Villonodular Synovitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pigmented Villonodular Synovitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pigmented Villonodular Synovitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pigmented Villonodular Synovitis Drug include Novartis AG, Bristol-Myers Squibb Co, Plexxikon Inc and F. Hoffmann-La Roche Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pigmented Villonodular Synovitis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pigmented Villonodular Synovitis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pigmented Villonodular Synovitis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pigmented Villonodular Synovitis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Pigmented Villonodular Synovitis Drug Segment by Company

Novartis AG

Bristol-Myers Squibb Co

Plexxikon Inc

F. Hoffmann-La Roche Ltd

Pigmented Villonodular Synovitis Drug Segment by Type

Nilotinib

Cabiralizumab

Emactuzumab

Mcs-110

Others

Pigmented Villonodular Synovitis Drug Segment by Application

Hospital

Clinic

Others

Pigmented Villonodular Synovitis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pigmented Villonodular Synovitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pigmented Villonodular Synovitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pigmented Villonodular Synovitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pigmented Villonodular Synovitis Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pigmented Villonodular Synovitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pigmented Villonodular Synovitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pigmented Villonodular Synovitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pigmented Villonodular Synovitis Drug Industry Trends Table 2. Pigmented Villonodular Synovitis Drug Industry Drivers Table 3. Pigmented Villonodular Synovitis Drug Industry Opportunities and Challenges Table 4. Pigmented Villonodular Synovitis Drug Industry Restraints Table 5. Global Pigmented Villonodular Synovitis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pigmented Villonodular Synovitis Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Manufacturers Table 9. Global Pigmented Villonodular Synovitis Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pigmented Villonodular Synovitis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pigmented Villonodular Synovitis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pigmented Villonodular Synovitis Drug Manufacturers, Product Type & Application Table 13. Global Pigmented Villonodular Synovitis Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pigmented Villonodular Synovitis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Nilotinib Table 17. Major Manufacturers of Cabiralizumab Table 18. Major Manufacturers of Emactuzumab Table 19. Major Manufacturers of Mcs-110 Table 20. Major Manufacturers of Others Table 21. Global Pigmented Villonodular Synovitis Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Pigmented Villonodular Synovitis Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Pigmented Villonodular Synovitis Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Type (2021-2026) Table 25. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Type (2027-2032) Table 26. Global Pigmented Villonodular Synovitis Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Pigmented Villonodular Synovitis Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Pigmented Villonodular Synovitis Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Type (2021-2026) Table 30. Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Others Table 34. Global Pigmented Villonodular Synovitis Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Pigmented Villonodular Synovitis Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Pigmented Villonodular Synovitis Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Application (2021-2026) Table 38. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Application (2027-2032) Table 39. Global Pigmented Villonodular Synovitis Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Pigmented Villonodular Synovitis Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Pigmented Villonodular Synovitis Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Application (2021-2026) Table 43. Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Application (2027-2032) Table 44. Global Pigmented Villonodular Synovitis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Pigmented Villonodular Synovitis Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Region (2021-2026) Table 47. Global Pigmented Villonodular Synovitis Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Pigmented Villonodular Synovitis Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Pigmented Villonodular Synovitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Pigmented Villonodular Synovitis Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Pigmented Villonodular Synovitis Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Pigmented Villonodular Synovitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Pigmented Villonodular Synovitis Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Pigmented Villonodular Synovitis Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Pigmented Villonodular Synovitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Pigmented Villonodular Synovitis Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Pigmented Villonodular Synovitis Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Pigmented Villonodular Synovitis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Pigmented Villonodular Synovitis Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Pigmented Villonodular Synovitis Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Region (2021-2026) Table 65. Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Region (2027-2032) Table 66. Novartis AG Company Information Table 67. Novartis AG Business Overview Table 68. Novartis AG Pigmented Villonodular Synovitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Novartis AG Pigmented Villonodular Synovitis Drug Product Portfolio Table 70. Novartis AG Recent Development Table 71. Bristol-Myers Squibb Co Company Information Table 72. Bristol-Myers Squibb Co Business Overview Table 73. Bristol-Myers Squibb Co Pigmented Villonodular Synovitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bristol-Myers Squibb Co Pigmented Villonodular Synovitis Drug Product Portfolio Table 75. Bristol-Myers Squibb Co Recent Development Table 76. Plexxikon Inc Company Information Table 77. Plexxikon Inc Business Overview Table 78. Plexxikon Inc Pigmented Villonodular Synovitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Plexxikon Inc Pigmented Villonodular Synovitis Drug Product Portfolio Table 80. Plexxikon Inc Recent Development Table 81. F. Hoffmann-La Roche Ltd Company Information Table 82. F. Hoffmann-La Roche Ltd Business Overview Table 83. F. Hoffmann-La Roche Ltd Pigmented Villonodular Synovitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. F. Hoffmann-La Roche Ltd Pigmented Villonodular Synovitis Drug Product Portfolio Table 85. F. Hoffmann-La Roche Ltd Recent Development Table 86. Key Raw Materials Table 87. Raw Materials Key Suppliers Table 88. Pigmented Villonodular Synovitis Drug Distributors List Table 89. Pigmented Villonodular Synovitis Drug Customers List Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Pigmented Villonodular Synovitis Drug Product Image Figure 2. Global Pigmented Villonodular Synovitis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pigmented Villonodular Synovitis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Pigmented Villonodular Synovitis Drug Sales (2021-2032) & (K Units) Figure 5. Global Pigmented Villonodular Synovitis Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pigmented Villonodular Synovitis Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Nilotinib Image Figure 9. Cabiralizumab Image Figure 10. Emactuzumab Image Figure 11. Mcs-110 Image Figure 12. Others Image Figure 13. Global Pigmented Villonodular Synovitis Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Pigmented Villonodular Synovitis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Type (2021-2032) Figure 16. Global Pigmented Villonodular Synovitis Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Pigmented Villonodular Synovitis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Pigmented Villonodular Synovitis Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Pigmented Villonodular Synovitis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Application (2021-2032) Figure 25. Global Pigmented Villonodular Synovitis Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Pigmented Villonodular Synovitis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Pigmented Villonodular Synovitis Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Pigmented Villonodular Synovitis Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Pigmented Villonodular Synovitis Drug Sales Market Share by Country (2021-2032) Figure 42. China Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Pigmented Villonodular Synovitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Pigmented Villonodular Synovitis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Pigmented Villonodular Synovitis Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Pigmented Villonodular Synovitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Pigmented Villonodular Synovitis Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Pigmented Villonodular Synovitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Pigmented Villonodular Synovitis Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Pigmented Villonodular Synovitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Pigmented Villonodular Synovitis Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Pigmented Villonodular Synovitis Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Nilotinib
  • Cabiralizumab
  • Emactuzumab
  • Mcs-110
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Bristol-Myers Squibb Co
  • Plexxikon Inc
  • F. Hoffmann-La Roche Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pigmented Villonodular Synovitis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pigmented Villonodular Synovitis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pigmented Villonodular Synovitis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pigmented Villonodular Synovitis Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pigmented Villonodular Synovitis Drug Market Dynamics
  1. 2.1 Pigmented Villonodular Synovitis Drug Industry Trends
  2. 2.2 Pigmented Villonodular Synovitis Drug Industry Drivers
  3. 2.3 Pigmented Villonodular Synovitis Drug Industry Opportunities and Challenges
  4. 2.4 Pigmented Villonodular Synovitis Drug Industry Restraints
3 Pigmented Villonodular Synovitis Drug Market by Manufacturers
  1. 3.1 Global Pigmented Villonodular Synovitis Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pigmented Villonodular Synovitis Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pigmented Villonodular Synovitis Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pigmented Villonodular Synovitis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pigmented Villonodular Synovitis Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pigmented Villonodular Synovitis Drug Manufacturers, Product Type & Application
  7. 3.7 Global Pigmented Villonodular Synovitis Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pigmented Villonodular Synovitis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pigmented Villonodular Synovitis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pigmented Villonodular Synovitis Drug Tier 1, Tier 2, and Tier 3
4 Pigmented Villonodular Synovitis Drug Market by Type
  1. 4.1 Pigmented Villonodular Synovitis Drug Type Introduction
  2. 4.1.1 Nilotinib
  3. 4.1.2 Cabiralizumab
  4. 4.1.3 Emactuzumab
  5. 4.1.4 Mcs-110
  6. 4.1.5 Others
  7. 4.2 Global Pigmented Villonodular Synovitis Drug Sales by Type
  8. 4.2.1 Global Pigmented Villonodular Synovitis Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Pigmented Villonodular Synovitis Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Pigmented Villonodular Synovitis Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Pigmented Villonodular Synovitis Drug Revenue by Type
  12. 4.3.1 Global Pigmented Villonodular Synovitis Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Pigmented Villonodular Synovitis Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Type (2021-2032)
5 Pigmented Villonodular Synovitis Drug Market by Application
  1. 5.1 Pigmented Villonodular Synovitis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Pigmented Villonodular Synovitis Drug Sales by Application
  6. 5.2.1 Global Pigmented Villonodular Synovitis Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pigmented Villonodular Synovitis Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Pigmented Villonodular Synovitis Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Pigmented Villonodular Synovitis Drug Revenue by Application
  10. 5.3.1 Global Pigmented Villonodular Synovitis Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pigmented Villonodular Synovitis Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Application (2021-2032)
6 Global Pigmented Villonodular Synovitis Drug Sales by Region
  1. 6.1 Global Pigmented Villonodular Synovitis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pigmented Villonodular Synovitis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Pigmented Villonodular Synovitis Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Pigmented Villonodular Synovitis Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pigmented Villonodular Synovitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pigmented Villonodular Synovitis Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pigmented Villonodular Synovitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pigmented Villonodular Synovitis Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pigmented Villonodular Synovitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pigmented Villonodular Synovitis Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pigmented Villonodular Synovitis Drug Revenue by Region
  1. 7.1 Global Pigmented Villonodular Synovitis Drug Revenue by Region
  2. 7.1.1 Global Pigmented Villonodular Synovitis Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pigmented Villonodular Synovitis Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Pigmented Villonodular Synovitis Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Pigmented Villonodular Synovitis Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pigmented Villonodular Synovitis Drug Revenue (2021-2032)
  8. 7.2.2 North America Pigmented Villonodular Synovitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pigmented Villonodular Synovitis Drug Revenue (2021-2032)
  11. 7.3.2 Europe Pigmented Villonodular Synovitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pigmented Villonodular Synovitis Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pigmented Villonodular Synovitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pigmented Villonodular Synovitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Pigmented Villonodular Synovitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Pigmented Villonodular Synovitis Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Bristol-Myers Squibb Co
  8. 8.2.1 Bristol-Myers Squibb Co Company Information
  9. 8.2.2 Bristol-Myers Squibb Co Business Overview
  10. 8.2.3 Bristol-Myers Squibb Co Pigmented Villonodular Synovitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Co Pigmented Villonodular Synovitis Drug Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Co Recent Developments
  13. 8.3 Plexxikon Inc
  14. 8.3.1 Plexxikon Inc Company Information
  15. 8.3.2 Plexxikon Inc Business Overview
  16. 8.3.3 Plexxikon Inc Pigmented Villonodular Synovitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Plexxikon Inc Pigmented Villonodular Synovitis Drug Product Portfolio
  18. 8.3.5 Plexxikon Inc Recent Developments
  19. 8.4 F. Hoffmann-La Roche Ltd
  20. 8.4.1 F. Hoffmann-La Roche Ltd Company Information
  21. 8.4.2 F. Hoffmann-La Roche Ltd Business Overview
  22. 8.4.3 F. Hoffmann-La Roche Ltd Pigmented Villonodular Synovitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 F. Hoffmann-La Roche Ltd Pigmented Villonodular Synovitis Drug Product Portfolio
  24. 8.4.5 F. Hoffmann-La Roche Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pigmented Villonodular Synovitis Drug Value Chain Analysis
  2. 9.1.1 Pigmented Villonodular Synovitis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pigmented Villonodular Synovitis Drug Production Mode & Process
  6. 9.2 Pigmented Villonodular Synovitis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pigmented Villonodular Synovitis Drug Distributors
  9. 9.2.3 Pigmented Villonodular Synovitis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst